Elective Induction at 39 Weeks

For decades, the obstetric community held a strong conviction that elective induction of labor increased the risk of cesarean delivery, particularly in nulliparous women with an unfavorable cervix. This belief was based on observational studies that compared induced women to those in spontaneous labor — a fundamentally flawed comparison because the alternative to induction is not spontaneous labor but continued expectant management (which may itself lead to cesarean for other indications). Retrospective studies from the 1990s-2000s using the correct comparator (induction vs expectant management) began to challenge this dogma, suggesting that induction did not increase — and might even decrease — cesarean rates. Caughey and colleagues' systematic review (2009) synthesized this observational evidence, demonstrating that elective induction at 39-40 weeks was not associated with increased cesarean delivery compared to expectant management.

The ARRIVE trial (A Randomized Trial of Induction Versus Expectant Management) was the landmark multicenter RCT that definitively answered this question. Published in the New England Journal of Medicine in 2018, ARRIVE randomized 6,106 low-risk nulliparous women at 39 weeks to elective induction versus expectant management. The results were striking and practice-changing: elective induction at 39 weeks significantly reduced the rate of cesarean delivery (18.6% vs 22.2%, P=0.049) while also reducing the incidence of gestational hypertensive disorders (9.1% vs 14.1%). There was no increase in adverse perinatal outcomes. The trial overturned decades of belief and generated intense debate about whether its findings should change practice for all low-risk women or only those meeting specific criteria.

Post-ARRIVE, several large observational studies examined the population-level impact of increasing 39-week induction rates. An analysis of US birth certificate data showed that 39-week induction rates increased significantly after ARRIVE publication, with concurrent decreases in cesarean delivery rates — supporting generalizability of the trial findings. The Swedish SWEPIS trial (2019) independently found that induction at 41 weeks reduced perinatal mortality compared to expectant management until 42 weeks, adding to the evidence that prolonging pregnancy beyond term carries risks. Secondary analyses of ARRIVE demonstrated that the cesarean reduction was consistent across subgroups including unfavorable cervix (Bishop score <5), race, BMI, and maternal age. However, concerns persisted about healthcare resource implications, as widespread 39-week induction would substantially increase obstetric workload.

ACOG (Practice Advisory 2018, reaffirmed 2023) stated that elective induction of labor at 39 weeks in low-risk nulliparous women is a 'reasonable option' that can be offered after shared decision-making, noting it does not increase cesarean delivery risk and may decrease hypertensive complications. SMFM concurred with this position. However, ACOG stopped short of recommending universal 39-week induction, emphasizing patient autonomy and adequate healthcare resources. NICE guidelines have been more cautious, not specifically endorsing 39-week elective induction for low-risk women. The RANZCOG acknowledges the ARRIVE evidence but similarly recommends shared decision-making rather than universal implementation.

ARRIVE has produced a genuine practice shift in many settings, with 39-week elective induction offered more widely to low-risk nulliparous women. However, implementation is uneven and debated. Key concerns include the generalizability to multiparous women (ARRIVE studied only nulliparas), the healthcare resource burden of increased inductions, whether benefits are maintained in community hospitals versus academic centers, and the impact on patient experience and satisfaction. The NUMBER needed to treat to prevent one cesarean was approximately 28, which some view as clinically meaningful and others as modest. Ongoing research examines patient-reported outcomes, cost-effectiveness, and the applicability of ARRIVE findings to diverse populations. The trial stands as a landmark example of how rigorous evidence can overturn deeply held clinical beliefs.